Arbor Biotechnologies appointed Mathew Pletcher, Ph.D., as its new Chief Scientific Officer, succeeding John Murphy who is retiring. Dr. Pletcher brings nearly 20 years of experience in gene therapy and rare diseases, having held leadership roles at companies like Weaver Biosciences, Astellas Gene Therapies, and Roche. His expertise is expected to accelerate Arbor's development of novel gene editing therapies, including their lead program ABO-101 for primary hyperoxaluria type 1 and CNS-focused ALS targets. This leadership change aims to strengthen Arbor's position in advancing next-generation genetic medicines for serious diseases without current cures.
CBAK Energy Technology reported a 99.3% year-over-year revenue increase to $69.62 million in Q1 2026, fueled by expanded production capacity and strong demand in light electric vehicles and battery raw materials. The battery segment grew 84.3%, with ...
NRx Pharmaceuticals reported a quarterly EPS of -$0.04, beating estimates and improving from last year, but revenue fell short at $1.07 million. The company is preparing for an FDA decision on its Preservative-Free Ketamine and has FDA clearance for ...
Rein Therapeutics completed a $57.5 million underwritten public offering by selling 57.5 million shares at $1.00 each, including the full exercise of an over-allotment option. The proceeds will fund the Phase 2 clinical trial of their drug LTI-03 for...
Streamex Corp. announced its second monthly yield distribution for GLDY, a gold-backed tokenized security, covering April 2026. The yield is generated through Streamex's institutional gold leasing program, which currently earns an annualized lease yi...
TOYO Co., Ltd announced a 177% increase in Q1 2026 revenue to $142.8 million, driven by higher solar cell and module sales. Net income rose to $28.4 million from a loss of $3.7 million in Q1 2025, with EBITDA improving significantly. The company reaf...
